BiosurgicalItems posts
Feed
Readers of this space know that the investment bias is toward large-cap companies with demonstrated business models, who have a competitive advantage in established markets, preferably with a favorable, global trend as a support. And with that in mind, Johnson & Johnson (NYSE: JNJ) is worth a review.Continue reading Johnson & Johnson: A stock for your child's college fund
| # | Blogger | Posts | Cmts |
|---|---|---|---|
| 1 | Joseph Lazzaro | 113 | 0 |
| 2 | Tom Johansmeyer | 103 | 2 |
| 3 | Connie Madon | 52 | 0 |
| 4 | Tom Taulli | 42 | 0 |
| 5 | Steven Mallas | 42 | 0 |
| 6 | Mark Fightmaster | 39 | 0 |
| 7 | Trey Thoelcke | 32 | 0 |
| 8 | Steven Halpern | 28 | 0 |
| 9 | Melly Alazraki | 25 | 0 |
| 10 | Zac Bissonnette | 24 | 0 |
| 11 | Paul Foster | 24 | 0 |
| 12 | Brent Archer | 21 | 0 |
| 13 | Jim Cramer | 21 | 0 |
| 14 | Jon Ogg | 21 | 0 |
| 15 | Brian White | 20 | 0 |
| 16 | Elizabeth Harrow | 17 | 0 |
| 17 | Eric Buscemi | 16 | 0 |
| 18 | Sheldon Liber | 13 | 0 |
| 19 | Michael Fowlkes | 8 | 0 |
| 20 | Beth Gaston Moon | 8 | 0 |
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
Google's plan for netbook PCs moves higher into the clouds
Closing Bell: Stock bulls and dollar death (DDRX,GMCR, PEET, SBUX, EBAY, CI, TECD)
So long peak oil, here comes peak uranium